AlzeCure Gets an Abstract on Phase II Clinical Data with ACD440 for Neuropathic Pain Accepted at Pain Conference
STOCKHOLM, SWEDEN / ACCESSWIRE / September 18, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), )...